What Is HRT? Types, Benefits, Risks, and How to Know If You're a Candidate

Hormones are the body's long-range communication system, traveling through the bloodstream to coordinate everything from body temperature and bone density to mood, libido, and cardiovascular function. For decades, that system runs with remarkable precision. Then, typically in the fourth or fifth decade of life, it begins to shift. Estrogen, progesterone, and testosterone decline. The downstream consequences accumulate quietly at first, then loudly. Hot flashes and night sweats disrupt sleep. Cognitive fog blunts concentration. Bone mineral density falls. Cardiovascular risk rises. For millions of people, hormone replacement therapy (HRT) is the clinical tool designed to address this transition directly, by restoring the hormonal environment the body depended on during its peak years.

Yet HRT is also one of the most misunderstood, and misrepresented, interventions in modern medicine. A single flawed study published in 2002 reshaped prescribing patterns for a generation, leaving countless patients undertreated and clinicians uncertain. Two decades of subsequent research have substantially revised that picture. Understanding what HRT actually is, what the evidence now says, and how to evaluate personal candidacy requires separating the signal from decades of noise. This article does exactly that.

Defining Hormone Replacement Therapy

Hormone replacement therapy is the clinical administration of exogenous hormones, hormones produced outside the body, to compensate for declining endogenous production. The term covers a broad family of interventions rather than a single protocol. In women, HRT most commonly refers to estrogen therapy, with or without progesterone, used to address the hormonal changes of perimenopause and menopause. In men, the equivalent intervention is testosterone replacement therapy (TRT). The umbrella also encompasses thyroid hormone replacement for hypothyroidism, DHEA supplementation, and in some longevity-oriented contexts, growth hormone optimization.

The fundamental logic of HRT is physiological: if a biological system depends on a hormone to function optimally, and that hormone is no longer being produced in adequate quantities, replacing it restores function. This is not pharmacological manipulation in the traditional sense. It is maintenance. The distinction matters because it shapes how risks and benefits should be weighed, not against doing nothing, but against the documented health consequences of sustained hormonal deficiency.

HRT is not pharmacological manipulation in the traditional sense. It is maintenance — restoring a biological environment the body depended on for decades.

The Hormones Involved and Why They Matter for Longevity

Estrogen is the primary sex hormone in women, produced mainly by the ovaries in the reproductive years. It acts on receptors distributed throughout nearly every tissue in the body: the brain, cardiovascular system, bone, skin, and gastrointestinal tract. Estrogen's role extends far beyond reproduction. It maintains arterial elasticity, supports serotonin and dopamine signaling in the brain, regulates bone remodeling by suppressing osteoclast activity, and modulates insulin sensitivity. When ovarian estrogen production falls at menopause, the effects of its withdrawal are systemic.

Progesterone is estrogen's counterpart in the female reproductive cycle. In the context of HRT, its primary clinical role is to protect the uterine lining from the proliferative effects of unopposed estrogen. But progesterone also has independent biological activity: it acts as a neurosteroid in the brain, binding to GABA receptors and contributing to sleep quality, mood regulation, and neuroprotection. This distinction becomes critically important when selecting the form of progesterone used in a protocol, a point addressed in detail in the section on formulation.

Testosterone is often framed as a male hormone, but this framing is imprecise. Women produce testosterone in the ovaries and adrenal glands throughout their lives, and it plays a meaningful role in libido, energy, mood, muscle maintenance, and bone density. Testosterone declines gradually in women across the reproductive years, and more sharply at menopause. In men, testosterone production begins declining at roughly one percent per year after age thirty, a trajectory known as andropause or late-onset hypogonadism. Low testosterone in men is associated with reduced lean muscle mass, increased adiposity, insulin resistance, reduced bone density, cognitive changes, and increased cardiovascular risk [1].

DHEA (dehydroepiandrosterone) is a precursor hormone produced by the adrenal glands that converts to both estrogen and testosterone in peripheral tissues. Its production peaks in the mid-twenties and declines steadily thereafter. Low DHEA levels have been associated with accelerated biological aging, though whether supplementation meaningfully reverses this remains an active area of investigation [2].

Menopause, Perimenopause, and the Window That Matters

Menopause is defined clinically as twelve consecutive months without a menstrual period, occurring on average at age fifty-one in the United States. But the hormonal transition begins years earlier, during perimenopause, when ovarian hormone production becomes erratic and eventually declines. This phase typically spans four to ten years and is marked by irregular cycles, sleep disruption, vasomotor symptoms (the clinical term for hot flashes and night sweats), mood changes, and early cognitive effects [3].

The timing of HRT initiation relative to this transition turns out to be one of the most clinically significant variables in the entire evidence base. Research now supports what is called the "critical window" or "timing hypothesis": estrogen therapy initiated within ten years of menopause onset, or before age sixty, carries a meaningfully different risk-benefit profile than therapy initiated later. Cardiovascular and cognitive benefits appear most pronounced when therapy begins early, during the window when tissues remain responsive to estrogen's protective effects [4]. This has profound implications for how HRT is evaluated and prescribed.

The timing of HRT initiation relative to menopause may matter as much as the decision to use HRT at all — a finding that reshapes how clinicians evaluate candidacy.

Premature ovarian insufficiency (POI), defined as ovarian failure before age forty, represents an important subset of patients for whom the case for HRT is particularly compelling. Women with POI face decades of estrogen deficiency that carries substantial long-term risk of osteoporosis, cardiovascular disease, and cognitive decline, risks that HRT directly addresses [5].

The 2002 WHI Study: What It Actually Found, and What It Got Wrong

No discussion of HRT is complete without addressing the Women's Health Initiative (WHI) study, published in 2002, which caused a seismic shift in prescribing behavior worldwide. The trial found that combined estrogen-progestin therapy was associated with increased risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism, and was stopped early. Prescription rates dropped by fifty percent within two years [6].

What received far less attention at the time was the study's significant methodological limitations. The average age of participants at enrollment was sixty-three, more than a decade past menopause. Most had pre-existing cardiovascular risk factors. The hormone formulation used was conjugated equine estrogen (CEE) combined with medroxyprogesterone acetate (MPA), a synthetic progestin with biological properties substantially different from bioidentical progesterone. Applying the findings from this older, already-symptomatic population to a newly menopausal woman in her early fifties represents a category error.

Subsequent re-analysis of WHI data stratified by age told a different story. Women who initiated therapy between ages fifty and fifty-nine had a significantly lower risk of coronary heart disease and all-cause mortality compared with placebo [4]. The estrogen-only arm of the WHI, which enrolled women who had undergone hysterectomy, actually showed a reduction in breast cancer risk [7]. The nuance that the 2002 headlines erased has been slowly, painstakingly restored by a decade of subsequent research.

Types of HRT: Formulations and Delivery Methods

Modern HRT is not a monolithic intervention. The form of hormone used, the delivery method, and the specific combination all carry distinct biological and clinical implications. Understanding these differences is fundamental to evaluating any HRT protocol.

Estrogen is available in several forms. Conjugated equine estrogen, derived from pregnant mare's urine and used in the original WHI study, is a mixture of estrogen compounds not identical to human estrogen. Bioidentical estrogens, including estradiol (the predominant estrogen in reproductive-age women) and estriol (a weaker estrogen more active in local tissues), are chemically identical to the hormones the human body produces. Estradiol is available as a patch, gel, spray, or oral tablet. The delivery route matters: transdermal estradiol bypasses first-pass liver metabolism, resulting in a more stable serum level and a lower risk of venous thromboembolism (blood clots) compared with oral estrogen [8]. For women seeking a transdermal option, the Estradiol Patch provides consistent delivery of bioidentical estradiol.

Bi-Est is a compounded formulation combining estradiol and estriol, typically in an 80/20 or 50/50 ratio. Estriol is preferentially active in vaginal and urinary tissues and has been explored for its potential to provide local benefits with a lower systemic estrogenic effect, though long-term comparative data with standardized estradiol products remain limited. The Bi-Est 50/50 Cream is one such compounded option used in personalized HRT protocols.

The choice of progestogen, the class of hormones that includes both progesterone and synthetic progestins, is arguably the most consequential formulation decision in female HRT. Synthetic progestins, particularly medroxyprogesterone acetate used in the WHI, act differently from progesterone at the cellular level. MPA has partial androgenic activity, may counteract some of estrogen's cardiovascular benefits, and has been associated with a greater increase in breast cancer risk compared with micronized progesterone in observational studies [9]. Micronized progesterone, which is bioidentical and metabolized to neurosteroid compounds, shows a more favorable profile in multiple domains including sleep, mood, and breast safety [10]. For women with an intact uterus using estrogen therapy, Micronized Progesterone represents the current evidence-preferred option for uterine protection.

For men, testosterone replacement therapy comes in several delivery forms: intramuscular or subcutaneous injections (testosterone cypionate or enanthate), topical gels and creams, transdermal patches, subcutaneous pellets, and oral formulations. Injectable testosterone, such as Testosterone Cypionate, produces reliable serum levels and is typically administered weekly or biweekly. Topical options, including Testosterone Topical Cream and Testosterone Gel, offer convenience and avoidance of injection but require attention to transfer risk (inadvertent skin contact with partners or children). Each delivery method has distinct pharmacokinetics, and the optimal choice depends on patient preference, lifestyle, and specific clinical goals.

What Conditions Does HRT Treat?

The symptom burden of menopause is often framed primarily around vasomotor symptoms, and HRT's effectiveness in reducing hot flashes and night sweats is well-established and robust, with symptom improvement in the seventy to ninety percent range [3]. But vasomotor symptom relief is only the entry point. The broader landscape of conditions that HRT addresses spans multiple organ systems.

Genitourinary syndrome of menopause (GSM), formerly called vaginal atrophy, encompasses the spectrum of changes to the vulva, vagina, and lower urinary tract that result from estrogen withdrawal. Vaginal dryness, dyspareunia (painful intercourse), urinary urgency, and recurrent urinary tract infections are among its manifestations. GSM is both underreported and undertreated. Estrogen therapy, delivered either systemically or locally, effectively reverses these changes [11].

Bone health represents one of HRT's most durable benefit profiles. Estrogen is a primary regulator of bone remodeling, suppressing the osteoclasts (cells that break down bone) and supporting osteoblast activity (cells that build it). Women lose bone density rapidly in the first five years after menopause. HRT has been shown in multiple trials to reduce the risk of vertebral, hip, and non-vertebral fractures [12]. Fracture risk reduction is one of the most compelling long-term arguments for HRT in women who discontinue therapy and experience accelerated bone loss.

Cardiovascular disease is the leading cause of death in women over sixty-five, and the estrogen withdrawal of menopause accelerates several cardiovascular risk pathways: LDL cholesterol rises, arterial stiffness increases, and blood pressure trends upward. The timing hypothesis is particularly relevant here. Observational studies and re-analyses of trial data consistently show that women who initiate HRT in early menopause have reduced rates of coronary heart disease and cardiovascular mortality [4]. Later initiation in women with established atherosclerosis does not show the same benefit and may carry harm, reinforcing the importance of the critical window.

Cognitive health is an emerging frontier for HRT research. Estrogen receptors are densely distributed in the hippocampus and prefrontal cortex, regions central to memory consolidation and executive function. Estrogen supports neuronal glucose metabolism, which declines in the perimenopausal brain, and has anti-inflammatory and neuroprotective effects [13]. Observational data suggest that women who use HRT during the critical window have a lower incidence of Alzheimer's disease later in life, though randomized trial evidence for cognitive outcomes remains less definitive [13]. This is an area where research is actively evolving.

In men, testosterone replacement addresses the clinical syndrome of hypogonadism: fatigue, reduced libido, loss of lean muscle mass (sarcopenia), increased visceral adiposity, mood changes including depression, and reduced bone density. Clinical trials including the recent Testosterone Trials (TTrials) confirmed improvements in sexual function, bone density, and anemia, with modest benefits on physical function and mood [14]. The cardiovascular safety of TRT has been clarified by the TRAVERSE trial, a large randomized controlled trial published in 2023 showing that testosterone replacement in middle-aged and older men with hypogonadism and elevated cardiovascular risk did not increase the rate of major adverse cardiovascular events compared with placebo [15].

HRT and Breast Cancer: Parsing the Actual Risk

Breast cancer risk is the concern most frequently cited by patients and clinicians when considering HRT, and it deserves precise, rather than generalized, treatment. The evidence shows that risk varies substantially by formulation, duration, and patient history.

The largest and most comprehensive meta-analysis on this question, published in The Lancet in 2019 and involving data from 108 epidemiological studies and 143,887 women with breast cancer, found that current use of combined estrogen-progestin HRT was associated with a modestly increased risk of breast cancer, while estrogen-only therapy in women without a uterus was associated with a smaller and less consistent increase [16]. Crucially, the excess risk attributable to HRT was quantified in absolute terms: for women using combined therapy for five years starting at age fifty, approximately one additional breast cancer case per fifty users over twenty years of follow-up. This is a meaningful risk that warrants discussion, but it is also a risk that can be contextualized against the baseline risk from obesity, alcohol consumption, or physical inactivity, all of which carry comparable or greater absolute risk magnitudes.

The absolute excess breast cancer risk from five years of combined HRT is approximately one additional case per fifty users over twenty years — a number that must be weighed against a backdrop of risks from lifestyle factors that rarely receive the same scrutiny.

The differential between synthetic progestins and micronized progesterone appears in this data as well. The EPIC cohort study and other large observational studies suggest that combined estrogen plus micronized progesterone carries a lower breast cancer risk than combined estrogen plus synthetic progestins [9]. This is one of the primary reasons that modern evidence-based HRT protocols favor bioidentical progesterone over synthetic alternatives.

Women with a prior personal history of breast cancer represent a specific population where the risk-benefit calculation shifts substantially, and individualized oncological guidance is essential. HRT is not contraindicated in all such women, but the decision requires careful evaluation of tumor receptor status, treatment history, and overall risk profile.

Testosterone in Women: An Underappreciated Component

Testosterone therapy for women remains one of the most under-prescribed and underappreciated components of female HRT, partly due to regulatory gaps (no testosterone product is currently licensed specifically for women in the United States) and partly due to lingering cultural discomfort with the association between testosterone and masculinity. The biology does not support that discomfort.

A 2019 systematic review and meta-analysis of randomized trials, commissioned by the Global Consensus Position Statement on testosterone therapy in women, found that testosterone was the only intervention to improve all domains of sexual dysfunction in women, including desire, arousal, orgasm, and pleasure [17]. Evidence for benefits in mood, cognitive function, bone density, and muscle mass in women is growing, though the evidence base for non-sexual outcomes remains less robust [17]. Off-label use with close clinical monitoring is the current standard approach in the United States, using male formulations at appropriately lower doses, a context in which a Women's Hormone Health program with individualized dosing and monitoring is particularly valuable.

HRT for Men: Testosterone Replacement Therapy in Context

For men, the conversation around HRT centers on testosterone, though the endocrine aging of men also involves changes in growth hormone, DHEA, and thyroid function. Late-onset hypogonadism is defined biochemically as total testosterone below 300 nanograms per deciliter (ng/dL) combined with clinical symptoms. But the relationship between testosterone levels and symptoms is not linear, and individual sensitivity to low-normal levels varies considerably. Some men with total testosterone of 350 ng/dL have significant symptom burden; others with 250 ng/dL are largely asymptomatic.

Before initiating testosterone replacement, clinical evaluation should assess the cause of low testosterone. Primary hypogonadism, where the testes fail to produce adequate testosterone, is distinguished from secondary or central hypogonadism, where the hypothalamus or pituitary gland fails to generate adequate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) signaling. In secondary hypogonadism, options exist to stimulate endogenous testosterone production rather than replacing it externally. Enclomiphene, a selective estrogen receptor modulator that increases LH and FSH output from the pituitary, is one such approach that preserves testicular function and fertility [18]. For men concerned about fertility preservation alongside testosterone optimization, Enclomiphene represents a meaningful alternative.

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing both LH signaling and intratesticular testosterone production. This leads to testicular atrophy and suppressed sperm production in most men on TRT, an effect that is generally reversible upon discontinuation but relevant for men considering future fertility. Co-administration of human chorionic gonadotropin (hCG) can preserve testicular function during TRT. A comprehensive Men's Hormone Health program addresses these considerations within a supervised protocol.

The TRAVERSE trial's cardiovascular safety data represent a significant advance in the evidence base for TRT. Earlier meta-analyses had raised concerns about cardiovascular risk, particularly in older men. The TRAVERSE trial, a prospective randomized double-blind trial of 5,204 men with hypogonadism, found no increase in cardiovascular events over a median 33-month follow-up, though it did identify an increase in pulmonary embolism and atrial fibrillation that warrants monitoring [15]. This nuance underscores why TRT should be supervised and not self-administered.

Evaluating Candidacy: Who Is HRT For?

Determining candidacy for HRT requires integrating symptom burden, laboratory findings, personal and family medical history, and patient preference into a coherent clinical picture. There is no single threshold that automatically qualifies or disqualifies a patient. The evaluation is inherently individualized.

For women, the conversation typically begins with symptom assessment. Moderate to severe vasomotor symptoms that affect quality of life represent the strongest evidence-based indication for HRT. Beyond symptoms, the evaluation considers: age and years since menopause onset (relevant to the timing hypothesis), uterine status (which determines whether progestogen is required), cardiovascular and thrombotic risk factors, personal and family history of breast cancer, bone density assessment, and hormonal bloodwork including estradiol, FSH, LH, total and free testosterone, and DHEA-S. The Menopause Society (formerly NAMS) 2022 Position Statement confirms that for most healthy women under sixty or within ten years of menopause onset, the benefits of HRT outweigh the risks [19].

For men, diagnostic evaluation includes fasting morning total testosterone (measured on at least two separate occasions), free testosterone (particularly relevant in men with elevated sex hormone-binding globulin, which reduces bioavailable hormone), LH, FSH, prolactin, and comprehensive metabolic and hematologic panels. Erythrocytosis (elevated red blood cell count) is a known risk of TRT that requires monitoring. Screening for obstructive sleep apnea, which can independently suppress testosterone and worsen with TRT, is also clinically indicated.

Absolute contraindications to HRT in women include active or recent breast cancer or other hormone-sensitive cancers, unexplained vaginal bleeding, active liver disease, and prior or current venous thromboembolism related to estrogen use. Relative contraindications, which require individualized risk-benefit analysis, include migraines with aura, hypertriglyceridemia, and active cardiovascular disease. For men, contraindications include prostate cancer, polycythemia, severe untreated sleep apnea, and active plans for biological paternity without co-management.

Monitoring, Dosing, and Duration

HRT is not a static prescription. Effective management involves initial dose titration, periodic reassessment of symptom control and side effects, and laboratory monitoring to ensure hormonal levels remain within physiological ranges rather than supraphysiological ones. The goal is restoration, not augmentation.

For women, follow-up typically occurs at three months after initiation to assess symptom response and side effects, with annual reviews thereafter. Transdermal estradiol doses are typically titrated to symptom relief within a range that keeps serum estradiol in the mid-follicular phase equivalent, roughly 50 to 100 picograms per milliliter. Progesterone dosing and delivery (oral versus vaginal) can be adjusted for sleep, mood, and tolerability. Testosterone in women, when used, is monitored by serum total testosterone to keep levels within the upper physiological female range.

For men, testosterone monitoring typically checks total and free testosterone, hematocrit (to detect erythrocytosis), estradiol (elevated estradiol from aromatization can cause gynecomastia and fluid retention), and PSA (prostate-specific antigen). The therapeutic target is generally a total testosterone level in the mid-to-upper normal range for healthy young men, roughly 500 to 700 ng/dL, though this is calibrated to individual symptom response and tolerance.

The question of treatment duration remains nuanced. There is no evidence-based upper limit for HRT duration in women who continue to have symptoms and who tolerate therapy well. The old practice of limiting HRT to five years was derived from the flawed WHI data and has been substantially revised. Current guidance supports individualized duration, with ongoing annual review of the risk-benefit balance [19].

HRT Within a Broader Longevity Framework

Hormone replacement therapy does not operate in isolation. It functions best as one component of a broader longevity-oriented health strategy that addresses nutrition, resistance exercise, sleep quality, metabolic health, and stress physiology in parallel. Hormonal optimization and lifestyle optimization are synergistic, not substitutes for each other.

The relationship between sex hormones and metabolic function is particularly relevant here. Estrogen deficiency is associated with increased visceral adiposity and insulin resistance, changes that drive cardiovascular and metabolic disease risk. HRT attenuates these shifts. Conversely, metabolic improvements from resistance training and dietary optimization support better hormonal signaling and may enhance the therapeutic response to HRT. For patients navigating both metabolic and hormonal challenges simultaneously, programs that address the full picture offer the most coherent clinical pathway.

Bone health, muscle preservation, and cardiovascular resilience are the three organ systems where the long-term consequences of sex hormone deficiency are most clinically significant, and these are precisely the systems most targeted by evidence-based longevity medicine. Framing HRT in this context, as a tool for preserving function across multiple biological systems rather than simply treating symptoms, reflects both the current science and the appropriate clinical aspiration. For patients who want to situate hormone therapy within a broader longevity program, Longevity Optimization offers an integrated clinical framework for addressing multiple healthspan determinants simultaneously.

Hormonal optimization and lifestyle optimization are not alternatives — they are synergistic. Each makes the other more effective.

The Future of HRT: Personalization and Precision

The trajectory of HRT research is moving decisively toward personalization. Pharmacogenomic variation in estrogen receptor genes, aromatase activity, and hormone-metabolizing enzymes like CYP3A4 and CYP1B1 means that two women on identical HRT protocols may experience substantially different biological responses and risk profiles. As genetic testing becomes more accessible and interpretable, these variants will increasingly inform initial formulation choices and dose adjustments.

The concept of the critical window is also evolving from a binary notion (before or after ten years post-menopause) toward a more continuous model that incorporates vascular age, inflammatory biomarkers, and neuroimaging findings. Research groups are actively investigating whether women with early signs of arterial stiffness or cognitive change represent a distinct population where the timing calculus is different. These questions will not be resolved by a single trial, but by the cumulative evidence of a generation of more precisely designed studies.

For men, ongoing research into the relationship between testosterone, metabolic syndrome, and cardiovascular risk is generating increasingly sophisticated models of when and how to intervene. The possibility that low testosterone is both a consequence and a driver of metabolic dysfunction, a bidirectional relationship rather than a simple deficiency state, is reshaping how TRT is positioned within the broader clinical picture of male aging.

Conclusion: Restoring the Signal

The question of what HRT is has a deceptively simple answer: it is the restoration of hormonal signals that the body depended on for decades, using the most biologically appropriate formulations available, with individualized protocols informed by a patient's unique risk profile, symptom burden, and long-term health goals. What complicates this straightforward biology is not the science itself but the decades of institutional hesitation generated by a single imperfect study, hesitation that left generations of patients undertreated and clinicians uneasy about an intervention for which the evidence base, properly understood, is substantial.

The modern picture is more complete. The timing hypothesis has been validated across multiple independent datasets. The distinction between synthetic progestins and bioidentical progesterone has meaningful clinical implications. Testosterone therapy in women, long marginalized, has robust evidence for sexual function and emerging evidence for broader quality of life. The cardiovascular safety of testosterone replacement in men has been characterized more precisely than ever before. And the framing of HRT as a longevity intervention, preserving bone, muscle, cardiovascular function, metabolic health, and cognitive resilience, brings it into alignment with how contemporary medicine understands the biology of aging.

For any individual considering HRT, the clinical conversation begins not with fear of the risks documented in 2002, but with a clear-eyed evaluation of the risks of doing nothing. Hormonal deficiency is not a benign default. It is a physiological state with documented consequences across multiple organ systems, consequences that compound over years and decades. The evidence now exists to make that conversation precise, personalized, and grounded in the science that patients deserve.